Cumulus Neuroscience Expands its Vision into the Japanese Market Through Collaboration with Shionogi & Co., Ltd. Cumulus Neuroscience enters the Japanese market through a partnership with Shionogi, aiming to enhance cognitive biomarker research for innovative therapies.

Cumulus Neuroscience Expands its Vision into the Japanese Market Through Collaboration with Shionogi & Co., Ltd. #Japan #Osaka #Cumulus_Neuroscience #Shionogi #NeuLogiq_Platform

Cumulus Neuroscience Welcomes Dr. Ricardo Sáinz Fuertes as New Board Chair Cumulus Neuroscience has appointed Dr. Ricardo Sáinz Fuertes as the new Chair of the Board, succeeding Dr. Ruth McKernan. His expertise aims to lead the company into the next phase of growth.

Cumulus Neuroscience Welcomes Dr. Ricardo Sáinz Fuertes as New Board Chair #United_Kingdom #digital_health #Belfast #Cumulus_Neuroscience #NeuLogiq_Platform

NeuLogiq® Platform Validates Electrophysiological Markers for Major Depression in Clinical Trials Cumulus Neuroscience presents groundbreaking findings demonstrating the NeuLogiq® Platform's ability to identify key electrophysiological signals in patients with Major Depressive Disorder, enhancing clinical trials.

NeuLogiq® Platform Validates Electrophysiological Markers for Major Depression in Clinical Trials #United_States #Scottsdale,_Arizona #Cumulus_Neuroscience #Major_Depressive_Disorder #NeuLogiq_Platform